Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
URLC10 + TTK + KOC1 peptide vaccine
- Development stage
- Unknown
- Lead developer
- Oncotherapy Science
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
URLC10 + TTK + KOC1 peptide vaccine is a trivalent cancer immunotherapy developed by the University of Tokyo in collaboration with Oncotherapy Science. It consists of three synthetic HLA-A*2402-restricted epitope peptides derived from tumor-associated antigens: up-regulated lung cancer 10 (URLC10), TTK protein kinase (TTK), and insulin-like growth factor-II mRNA binding protein 3 (KOC1, also known as IMP3). These antigens are frequently overexpressed in non-small cell lung cancer (NSCLC) but have limited expression in normal tissues. The vaccine is administered via subcutaneous injection after being emulsified with the adjuvant Montanide ISA 51 (Incomplete Freund's Adjuvant) to enhance the induction of antigen-specific cytotoxic T lymphocytes (CTLs). It is primarily investigated for the treatment of patients with advanced or refractory HLA-A*2402-positive NSCLC.
- Other names
- URLC10, TTK, and KOC1 multiple-peptide vaccineHLA-A*2402 restricted URLC10, TTK, and KOC1 peptide vaccine
02
Targets
KOC1-HLA-A*24:02 (Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) peptide-HLA-A*24:02 complex)TTK-HLA-A*24:02 (TTK protein kinase – Human leukocyte antigen A*24:02 complex)URLC10/HLA-A*24:02 (URLC10 peptide-HLA-A*24:02 complex)
Beyond the preview
Go deeper on URLC10 + TTK + KOC1 peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on URLC10 + TTK + KOC1 peptide vaccine.